Cargando…
Correlation between Therapeutic Efficacy of CD34(+) Cell Treatment and Directed In Vivo Angiogenesis in Patients with End-Stage Diffuse Coronary Artery Disease
BACKGROUND: This study was aimed at testing the association between the therapeutic efficacy of CD34(+) cell treatment in patients with end-stage diffuse coronary artery disease as reflected in angiographic grading and results of directed in vivo angiogenesis assay (DIVAA) on their isolated peripher...
Autores principales: | Huang, Tien-Hung, Sun, Cheuk-Kwan, Chen, Yi-Ling, Sung, Pei-Hsun, Chu, Chi-Hsiang, Lee, Mel S., Lin, Yuan-Ping, Yip, Hon-Kan, Lee, Fan-Yen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924973/ https://www.ncbi.nlm.nih.gov/pubmed/29760742 http://dx.doi.org/10.1155/2018/9591421 |
Ejemplares similares
-
Baseline factors identified for the prediction of good responders in patients with end-stage diffuse coronary artery disease undergoing intracoronary CD34+ cell therapy
por: Sung, Pei-Hsun, et al.
Publicado: (2020) -
Reduced effects of cardiac extracorporeal shock wave therapy on angiogenesis and myocardial function recovery in patients with end-stage coronary artery and renal diseases
por: Sung, Pei-Hsun, et al.
Publicado: (2021) -
Intracoronary Injection of Autologous CD34+ Cells Improves One-Year Left Ventricular Systolic Function in Patients with Diffuse Coronary Artery Disease and Preserved Cardiac Performance—A Randomized, Open-Label, Controlled Phase II Clinical Trial
por: Sung, Pei-Hsun, et al.
Publicado: (2020) -
Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial
por: Lee, Mel S., et al.
Publicado: (2017) -
Safety and efficacy of intrarenal arterial autologous CD34+ cell transfusion in patients with chronic kidney disease: A randomized, open‐label, controlled phase II clinical trial
por: Yang, Chih‐Chao, et al.
Publicado: (2020)